Related Experiment Video
Updated: Apr 30, 2026
05:53
Candidate Gene Testing in Clinical Cohort Studies with Multiplexed Genotyping and Mass Spectrometry
Published on: June 21, 2018
9.2K
Pharmacogenomics: from cell to clinic (Part 1)
Gérard Siest1, Rui Medeiros, Bohuslav Melichar
1University of Lorraine, UMR INSERM U.1122 "IGE-PCV", Nancy, France.
Pharmacogenomics
|May 7, 2014
Summary
The European Society of Pharmacogenomics and Theranostics (ESPT) conference highlighted pharmacogenomics and biomarkers in medical oncology, focusing on solid tumors and clinical implementation for personalized medicine.
Area of Science:
- Pharmacogenomics and Theranostics
- Medical Oncology
- Personalized Medicine
Background:
- The European Society of Pharmacogenomics and Theranostics (ESPT) conference convened in Lisbon, Portugal, with 250 international participants.
- The event featured 50 oral presentations, 5 lunch symposia, and 83 posters, covering advancements in pharmacogenomics.
Framework:
- Focus on pharmacogenomics and biomarkers in medical oncology, particularly for solid tumors.
- Keynote lectures by Ann K Daly and Magnus Ingelman-Sundberg provided foundational insights.
- Discussions included clinical implementation of pharmacogenomic tests and the role of transporters.
Implementation:
- Exploration of stem cells and novel tools in pharmacogenomics and drug discovery.
- Emphasis on the clinical translation of pharmacogenomics to achieve personalized medicine.
- The conference facilitated knowledge exchange on integrating pharmacogenomic data into clinical practice.
Implications:
- Advancements in pharmacogenomics promise more targeted and effective cancer treatments.
- The integration of pharmacogenomic tests is crucial for the future of personalized medicine.
- Continued research and collaboration are essential for advancing drug discovery and clinical applications.
Related Concept Videos
01:29Pharmacogenomics: Identification of New Drug Targets
121
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
121
01:29Pharmacogenetics and Pharmacogenomics: Overview
253
Pharmacogenetics and pharmacogenomics examine how genetic factors influence an individual's response to drugs. While pharmacogenetics focuses on the impact of specific genetic variants on drug effects, pharmacogenomics takes a broader approach, studying how genetic variation across populations contributes to differences in drug responses. These fields aim to explain why individuals may experience varying levels of efficacy or adverse reactions to the same medication.Variability in drug...
253
01:29Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
159
Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
159
01:27Pharmacogenetics of Drug Metabolism: Overview
194
Genetic polymorphism in drug metabolism is crucial to the inter-individual variability observed in drug responses. Drug metabolism primarily involves the chemical modification of drugs and other xenobiotics to enhance their elimination by increasing their polarity. Two main classes of enzymes mediate this biotransformation process: Phase I enzymes, primarily cytochrome P450s, catalyze oxidation and reduction reactions, while other enzymes, such as esterases, mediate hydrolysis, and Phase II...
194
01:27Principles of Pharmacogenetics: Types of Genetic Variants
138
The human genome is over 99.9% identical between individuals, yet genetic differences exist at millions of bases. The human genome contains approximately 3 million variant positions per individual, many of which are heterozygous, contributing to genetic diversity and individual traits. Genetic variations include single-nucleotide polymorphisms (SNPs), insertions, deletions, and copy number variations (CNVs).SNPs, the most common variation, involve single-base changes in DNA. These can be...
138
01:28Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes
338
Cytochrome P450 (CYP450) enzymes are a superfamily of heme-containing monooxygenases that play a pivotal role in Phase I drug metabolism by catalyzing oxidation and reduction reactions.These enzymes transform lipophilic xenobiotics into more hydrophilic metabolites, facilitating subsequent Phase II conjugation and eventual excretion. The CYP450 family is classified into families (e.g., CYP1–CYP3) and subfamilies (e.g., CYP2A, CYP2C), based on amino acid sequence homology.CYP450...
338